J&J(JNJ) - 2025 Q3 - Earnings Call Presentation

Financial Performance - Johnson & Johnson's worldwide sales for Q3 2025 reached $24.0 billion, a 6.8% increase compared to Q3 2024[1] - Diluted earnings per share (EPS) increased by 91.0% to $2.12[2] - Adjusted earnings per share increased 15.7% to $2.80[5] Segment Performance - Worldwide Innovative Medicine sales reached $15.6 billion, with a reported increase of 6.8% and an operational increase of 5.3%, impacted by Stelara by approximately -1070 basis points[3] - Worldwide MedTech sales reached $8.4 billion, with a reported increase of 6.8% and an operational increase of 5.6%[8] Regional Sales - U.S sales increased 6.2% to $13.7 billion[40] - International sales increased 7.6% to $10.3 billion[40] Guidance - The company increased operational sales guidance to 5.1% and maintained adjusted operational EPS guidance at 7.0%[55]